Intrigue: phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib

Nemunaitis, J.; Bauer, S.; Blay, J.Y.; Choucair, K.; Gelderblom, H.; George, S.; ... ; Heinrich, M.C. (2020)

Article / Letter to editor

Ripretinib (DCC-2618) is a novel, type II tyrosine switch control inhibitor designed to broadly inhibit activating and drug-resistant mutations in KIT and PDGFRA. Ripretinib has emerged as a promising investigational agent for the treatment of gastrointestinal stromal tumor owing to targeted inhibition of secondary resistance mutations that may develop following treatment with prior line(s) of tyrosine kinase inhibitors. Here we describe the rationale and design of intrigue (NCT03673501), a global, randomized (1:1), open-label, Phase III study comparing the safety and efficacy of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor following imatinib. The primary end point is progressionfree survival and key secondary objectives include objective response rate and overall survival.

• DCC-2618
• gastrointestinal stromal tumor
• KIT
• PDGFRA
• Phase III trial
• receptor tyrosine kinase
• ripretinib
• sarcoma
• targeted therapy
• tyrosine kinase inhibitor

• All authors: Nemunaitis, J.; Bauer, S.; Blay, J.Y.; Choucair, K.; Gelderblom, H.; George, S.; Schoffski, P.; Mehren, M. von; Zalcberg, J.; Achour, H.; Ruiz-Soto, R.; Heinrich, M.C.
• Date: 2020-01-01
• Journal: Future Oncology
• Volume: 16
• Issue: 1
• Pages: 4251 - 4264
• DOI: doi:10.2217/fon-2019-0633
• Link: https://www.futuremedicine.com/doi/10.2217/fon-2019-0633